Precision Optics Corporation, Inc. Announces Operating Results for the Second Quarter and Six Months of Fiscal Year 2018


GARDNER, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the “Company”) today announced operating results on an unaudited basis for its fiscal year 2018 second quarter and six months ended December 31, 2017.

Financial highlights include:

  • 35% increase in quarterly revenues: $813,000 second quarter fiscal 2018 revenues compared to $602,000 in the second quarter of fiscal 2017;
  • 27% increase in six month revenues: $1,841,000 six month fiscal 2018 revenues compared to six month 2017 revenues of $1,451,000;
  • Increased gross margins in Fiscal 2018: 37% gross margin in fiscal 2018 second quarter and six months, compared to 25% and 22% in fiscal 2017 second quarter and six months, respectively;
  • Reduced net loss in Fiscal 2018: Second quarter and six months fiscal 2018 net loss of $60,000 and $89,000, respectively, compared to $312,000 and $605,000 in fiscal 2017 second quarter and six months, respectively.

Commenting on the second quarter results, Joseph Forkey, Company CEO said, “Continued strength in our financial performance at current sales levels reinforces our confidence that the Company will achieve improved operational results when increasing manufacturing orders raise overall revenue levels. Our focus on controlling costs, optimizing the use of resources and maximizing production yields is reflected in increased revenues and gross margins with simultaneous reductions in operating expenses and net losses in both the quarter and six months ended December 31, 2017.”

Dr. Forkey continued, “Our sustained pipeline of engineering design projects calls upon our many unique technical capabilities including Microprecision™ micro-optics, custom design of medical grade cameras and endoscopes, CMOS imaging systems, illumination technologies, and 3D endoscopes. We are pleased to report that a number of engineering projects are transitioning to production, and we have now received production orders from three existing customers totaling over $2.1 Million with deliveries scheduled over the next eighteen months. Each of these three products utilizes our proprietary Microprecision™ technologies, and should significantly contribute to increasing revenues and continuously improving operational results in coming quarters.”

Quarterly Conference Call Details
The Company has scheduled a conference call to discuss the fiscal Second quarter 2018 financial results for Wednesday, February 14, 2018 at 5:00 PM Eastern Time. To participate in the conference call, please dial 1-844-826-3042 toll free from the U.S., or 1-412-317-5187 for international callers, and ask to be connected to the Precision Optics, Corp. call.

An audio replay of the conference call will be available approximately one hour after the conclusion of the call and will be made available until February 28, 2018. The audio replay can be accessed by dialing 1-877-344-7529 toll free from the U.S., or 1-412-317-0088 for international callers, and entering Replay Access Code 10116867.

About Precision Optics Corporation
Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, MicroprecisionTM micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for a broad range of customers including some of the largest global medical device companies. The Company’s innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures.  The Company’s website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.

About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.   

Company Contact:
Precision Optics Corporation
22 East Broadway
Gardner, Massachusetts, 01440-3338
Telephone: 978-630-1800

Investor Contact:
PCG Advisory Group
Kirin M. Smith
Chief Operating Officer
Telephone: 646-863-6519
Email: Ksmith@PCGAdvisory.com
Website: www.PCGAdvisory.com

Following are the Company’s consolidated balance sheets as of December 31, 2017 and June 30, 2017, and statements of operations for the three and six months ended December 31, 2017 and 2016 and statements of cash flows for the six months ended December 31, 2017 and 2016 (unaudited):

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

  December 31,
2017
  June 30,
2017
 
ASSETS        
CURRENT ASSETS        
Cash and Cash Equivalents $381,752  $118,405 
Accounts Receivable, net  753,152   468,548 
Inventories, net  987,791   1,055,447 
Prepaid Expenses  78,432   55,985 
Total Current Assets  2,201,127   1,698,385 
PROPERTY AND EQUIPMENT        
Machinery and Equipment  2,507,190   2,507,190 
Leasehold Improvements  553,596   553,596 
Furniture and Fixtures  148,303   148,303 
   3,209,089   3,209,089 
         
Less: Accumulated Depreciation and Amortization  (3,152,639)  (3,136,835)
Net Fixed Assets  56,450   72,254 
         
Patents, net  47,275   30,086 
         
TOTAL ASSETS $2,304,852  $1,800,725 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
CURRENT LIABILITIES        
Current Portion of Capital Lease Obligation $8,672  $8,391 
Accounts Payable  699,507   694,958 
Customer Advances  463,289   180,137 
Accrued Employee Compensation  179,601   189,783 
Accrued Professional Services  107,500   71,000 
Accrued Warranty Expense  25,000   25,000 
Other Accrued Liabilities  46,125   49,512 
Total Current Liabilities  1,529,694   1,218,781 
         
Capital Lease Obligation, net of current portion  19,156   23,564 
         
STOCKHOLDERS’ EQUITY        
Common Stock, $0.01 par value - Authorized - 50,000,000 shares; Issued
and Outstanding – 10,095,139 shares at December 31, 2017 and
8,872,916 shares at June 30, 2017
  100,952   88,729 
Additional Paid-in Capital  45,414,893   45,140,383 
Accumulated Deficit  (44,759,843)  (44,670,732)
Total Stockholders’ Equity  756,002   558,380 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $2,304,852  $1,800,725 
         

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED
DECEMBER 31, 2017 AND 2016
(UNAUDITED)

  Three Months
Ended December 31,
  Six Months
Ended December 31,
 
  2017  2016  2017  2016 
Revenues $812,773  $601,590  $1,841,519  $1,451,138 
                 
Cost of Goods Sold  512,551   453,183   1,154,555   1,135,680 
Gross Profit  300,222   148,407   686,964   315,458 
                 
Research and Development Expenses, net  90,031   119,215   208,458   236,207 
                 
Selling, General and Administrative Expenses  270,035   342,487   566,619   686,269 
                 
Gain on Sale of Assets  -   (1,200)  -   (1,515)
Total Operating Expenses  360,066   460,502   775,077   920,961 
                 
Operating Loss  (59,844)  (312,095)  (88,113)  (605,503)
                 
Interest Expense  (482)  -   (998)  - 
                 
Net Loss  (60,326)  (312,095)  (89,111)  (605,503)
                 
Loss Per Share:                
Basic $(0.01) $(0.04) $(0.01) $(0.08)
Diluted $(0.01) $(0.04) $(0.01) $(0.08)
                 
Weighted Average Common Shares Outstanding:                
Basic  9,979,197   8,104,800   9,543,810   7,822,191 
Diluted  9,979,197   8,104,800   9,543,810   7,822,191 
                 

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED
DECEMBER 31, 2017 AND 2016
(UNAUDITED)

  Six Months
Ended December 31,
 
  2017  2016 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net Loss $(89,111) $(605,503)
Adjustments to Reconcile Net Loss to Net Cash Provided From (Used In) Operating Activities -        
Depreciation and Amortization  15,804   16,019 
Gain on Sale of Assets     (1,515)
Stock-based Compensation Expense  33,028   110,433 
Non-cash Consulting Expense  (3,387)  17,400 
Changes in Operating Assets and Liabilities -        
Accounts Receivable, net  (284,604)  308,293 
Inventories, net  67,656   35,560 
Prepaid Expenses  (22,447  (5,915
Accounts Payable  41,586   (168,433
Customer Advances  283,152   37,100 
Accrued Liabilities  26,318   (22,880)
Net Cash Provided From (Used In) Operating Activities  67,995   (279,441
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
         
Additional Patent Costs  (17,189  (5,848)
Purchases of Property and Equipment     (25,843)
Proceeds from Sale of Assets     1,515 
Net Cash Used In Investing Activities  (17,189  (30,176)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Payment of Capital Lease Obligation  (4,127)  (3,864)
Gross Proceeds from Private Placement of Common Stock  210,001   780,000 
Gross Proceeds from Exercise of Stock Purchase Warrants  6,667   - 
Net Cash Provided From Financing Activities  212,541   776,136 
         
NET INCREASE IN CASH AND CASH EQUIVALENTS  263,347   466,519 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD  118,405   50,059 
         
CASH AND CASH EQUIVALENTS, END OF PERIOD $381,752  $516,578 
         
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:        
Issuance of Common Stock in Settlement of Accounts Payable $40,000  $ 
Offering Costs Included in Accounts Payable $2,963  $